KR101914441B1 - Cosmetic compositions for improving skin moisturizing comprising fucosterol - Google Patents
Cosmetic compositions for improving skin moisturizing comprising fucosterol Download PDFInfo
- Publication number
- KR101914441B1 KR101914441B1 KR1020170056923A KR20170056923A KR101914441B1 KR 101914441 B1 KR101914441 B1 KR 101914441B1 KR 1020170056923 A KR1020170056923 A KR 1020170056923A KR 20170056923 A KR20170056923 A KR 20170056923A KR 101914441 B1 KR101914441 B1 KR 101914441B1
- Authority
- KR
- South Korea
- Prior art keywords
- fucoserol
- skin
- extracted
- kelp
- seaweed
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 16
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 title description 11
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 title description 11
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 title description 11
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 title description 11
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 title description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241001474374 Blennius Species 0.000 claims description 15
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 241001609213 Carassius carassius Species 0.000 claims description 5
- 241000333599 Silvetia siliquosa Species 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 241000009328 Perro Species 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 240000006677 Vicia faba Species 0.000 claims description 2
- 235000010749 Vicia faba Nutrition 0.000 claims description 2
- 235000002098 Vicia faba var. major Nutrition 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 241000473391 Archosargus rhomboidalis Species 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 230000009759 skin aging Effects 0.000 abstract description 13
- 108010035532 Collagen Proteins 0.000 abstract description 12
- 102000008186 Collagen Human genes 0.000 abstract description 12
- 229920001436 collagen Polymers 0.000 abstract description 12
- 230000037303 wrinkles Effects 0.000 abstract description 11
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 108060005980 Collagenase Proteins 0.000 abstract description 5
- 102000029816 Collagenase Human genes 0.000 abstract description 5
- 229960002424 collagenase Drugs 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000009472 formulation Methods 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000037319 collagen production Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 101150014058 MMP1 gene Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 108700004333 collagenase 1 Proteins 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 206010051246 Photodermatosis Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- -1 fucosterol compound Chemical class 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000008845 photoaging Effects 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 230000011382 collagen catabolic process Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 229940113124 polysorbate 60 Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- CEAYCPAHSNTNGO-UHFFFAOYSA-M sodium;ethane-1,2-diamine;acetate Chemical compound [Na+].CC([O-])=O.NCCN CEAYCPAHSNTNGO-UHFFFAOYSA-M 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 퓨코스테롤의 새로운 용도에 관한 것으로, 더욱 상세하게는 퓨코스테롤을 유효성분으로 포함하는 피부주름 또는 피부노화 개선용 화장료 조성물에 관한 것이다. 본 발명의 조성물은 콜라겐 분해효소를 억제하고, 콜라겐의 생성을 촉진하는 효능이 뛰어나 피부의 노화 개선 및 피부보습력 증진에 효과적이다.The present invention relates to a new use of fucoserol, and more particularly to a cosmetic composition for improving skin wrinkles or skin aging comprising fucoserol as an active ingredient. The composition of the present invention is effective for inhibiting collagenase and promoting the production of collagen, thereby improving skin aging and improving skin moisturizing power.
Description
본 발명은 퓨코스테롤(fucosterol)의 새로운 용도에 관한 것으로, 더욱 상세하게는 퓨코스테롤을 유효성분으로 포함하는 피부노화 개선 또는 피부 보습용 화장료 조성물, 건강기능식품 조성물 및 치료용 약학적 조성물에 관한 것이다.The present invention relates to a novel use of fucosterol, and more particularly to a cosmetic composition for improving skin aging or skin moisturizing, a health functional food composition and a therapeutic pharmaceutical composition comprising fucosterol as an active ingredient .
피부는 외부환경의 자극으로부터 체내의 기관들을 보호해주며, 체온조절 등의 생체 항상성 유지에 중요한 역할을 한다. 이러한 피부는 여러 가지 내·외적 요인에 의해서 노화가 발생되며, 크게 유전적 원인에 의한 내인성 노화와 환경적 원인에 의한 외인성 노화로 구분된다. 이 중, 광노화는 자외선(ultraviolet; UV)에 의한 노화를 의미한다. 최근 환경오염으로 인한 오존층 파괴는 자외선의 양을 증가시켰고 이에 따라 광노화에 대한 연구가 주목되고 있다(Wang SQ et al., Dermatol. Ther. 23(1):31-47, 2010). 광노화된 피부에서는 거칠어짐, 탄력 손실, 주름 발생 및 불규칙한 색소 침착 등과 같은 외관상의 특징이 관찰되며, 이 중 광노화의 주된 연구 분야는 피부 주름의 변화에 대한 것이다. 상기 광노화에 의한 피부 주름 형성에 관해 피부의 주요 구성성분인 콜라겐(collagen)의 합성, 분해 및 수분 함유량 등의 기초적인 생리 대사 변화에 대한 연구 결과가 다수 보고되고 있다(Brenneisen et al., Ann. N. Y. Acad. Sci., 973:31-43, 2002). Skin protects the organs in the body from external stimuli and plays an important role in the maintenance of body homeostasis, such as body temperature control. Such skin is aged by various internal and external factors and is divided into endogenous aging by genetic cause and exogenous aging by environmental cause. Among them, photoaging refers to aging by ultraviolet (UV). Recently, the destruction of the ozone layer due to environmental pollution has increased the amount of ultraviolet rays, and accordingly, research on photoaging has been attracting attention (Wang SQ et al., Dermatol. Ther. 23 (1): 31-47, 2010). In the photoaged skin, appearance characteristics such as roughness, loss of elasticity, wrinkles and irregular pigmentation are observed. Among them, the main research field of photoaging is the change of the skin wrinkles. There have been many reports on the basic physiological metabolism changes such as synthesis, degradation, and moisture content of collagen, which is a major constituent of skin, in the formation of skin wrinkles by photoaging (Brenneisen et al., Ann. NY Acad. Sci., 973: 31-43, 2002).
피부 진피층에 존재하는 콜라겐은 피부 전체 건조 중량의 약 70-80%를 차지하며 탄력섬유인 엘라스틴(elastin)과 함께 피부의 탄력을 주관하는 것으로 알려져 있다. 특히 자외선에 의해 활성 산소종(reactive oxygen species) 생성이 증가되고 피부의 효소적·비효소적 항산화 방어체계가 붕괴되어 콜라겐의 분해 증가 및 생합성을 감소시켜 진피층 내의 콜라겐이 현저하게 감소된다(Bickers DR, Athar M, J. Invest. Dermatol., 126(12):2565-2575, 2006). 상기 콜라겐 감소에 중요한 영향을 미치는 것은 콜라겐 분해 효소(MMPs; matrix metalloproteinases)로, 이는 세포외기질(extracellular matrix)과 기저막(basement membrane)의 분해에 관여 한다. 상기 효소는 자외선에 의해 활성이 증가되며 이를 억제함으로써 자외선에 의해 유도되는 피부 두께 증가 및 주름 형성이 감소된다는 연구 결과들이 보고되어 있다(Inomata S et al., J. Invest. Dermatol., 120(1):128-134, 2003). 따라서 광노화의 예방 및 치료를 위해서는 MMPs를 조절하는 것이 효과적인 방법이다. Collagen in the dermal layer of the skin occupies about 70-80% of the total dry weight of the skin and it is known to control the elasticity of the skin along with the elastic fiber elastin. Particularly, ultraviolet rays increase the production of reactive oxygen species, collapse of enzymatic and non-enzymatic antioxidant defenses of skin, and collagen degradation and biosynthesis are reduced, resulting in marked reduction of collagen in the dermis (Bickers DR , Athar M, J. Invest. Dermatol., 126 (12): 2565-2575, 2006). Important collagen degradation factors are matrix metalloproteinases (MMPs), which are involved in the degradation of extracellular matrix and basement membrane. Studies have been reported that the enzyme increases activity by ultraviolet rays and inhibits it, leading to an increase in skin thickness and wrinkle formation induced by ultraviolet light (Inomata S et al., J. Invest. Dermatol., 120 ): 128-134, 2003). Therefore, it is effective to control MMPs for prevention and treatment of photoaging.
피부 진피층의 구성성분인 히알루론산(hyaluronic acid)은 진피층의 콜라겐 사이를 채워 피부의 보습 및 탄력을 유지시키는 성분이다. 특히, 자외선은 히알루론산의 양을 감소시켜 피부 내 수분 함유량을 감소시키고 경피 수분 손실량을 증가시켜 피부 장벽의 손상을 야기한다. 이로 인해 피부가 거칠어지고 탄력성이 감소되어 주름이 생성된다(Baumann L, J. Pathol., 211(2):241-251, 2007). 즉, 피부의 보습력 상실은 피부노화의 주요 원인이 된다.Hyaluronic acid, a component of the skin's dermis layer, is a component that keeps the skin moisturized and elastic by filling the collagen between the dermis layers. In particular, ultraviolet light reduces the amount of hyaluronic acid to reduce moisture content in the skin and increase the amount of transdermal water loss, resulting in damage to the skin barrier. This results in rough skin and reduced elasticity, resulting in wrinkles (Baumann L, J. Pathol., 211 (2): 241-251, 2007). That is, loss of moisture of the skin is a main cause of skin aging.
주름 개선에 대한 전 세계 소비자의 기대와 관심은 레티놀을 시작으로 하여 2000년대부터 천연물추출성분, 아데노신, 세포성장인자 등 그 종류와 기능이 다양해지고 있는 추세이다(Lee EJ et al., Journal of the Korean Society of Cosmetology, 17(1):127-133, 2011). 기존의 방법은 레티노이드, 아스코르브산, 토코페롤 및 히알루론산 등을 함유하는 화장료나 의약품을 제조하여 사용하는 것이다. 하지만 현재 개발되고 있는 피부 주름 개선 또는 항노화를 위한 유효성분들은 일부 화장품 원료로 사용할 수 없거나 매우 불안정하고 피부로의 전달이 용이하지 않아 특별한 안정화 시스템과 전달체계가 필요하며, 피부주름의 개선효과가 가시적이지 않다는 문제점이 있다. 상기 피부 주름 개선 유효성분인 레티노이드는 콜라겐 분해효소를 저해하고 콜라겐 합성을 증가시킴으로써 주름 형성 및 탄력 감소 등의 광노화 현상을 개선하기 위해 이용되고 있다. 그러나 자외선에 매우 민감하여 쉽게 화학적인 변화를 일으키므로 피부 자극 등의 부작용을 일으키며, 장기적으로 사용해야 효과가 나타난다는 문제점이 있다(Rabe JH, J. Am. Acad. Dermatol., 55:1-19, 2006). 상기 유효성분들의 문제점을 해결하기 위하여 안정성이 입증된 천연물 유래의 유효성분에 대한 연구가 요구되고 있다. Consumers' expectation and interest in wrinkle improvement has been diversified from retinol to natural products extract, adenosine, and cell growth factor from the 2000s (Lee EJ et al., Journal of the Korean Society of Cosmetology, 17 (1): 127-133, 2011). Conventional methods are to manufacture and use cosmetic products or medicines containing retinoid, ascorbic acid, tocopherol, hyaluronic acid and the like. However, the active ingredients for the improvement of skin wrinkles or anti-aging currently being developed can not be used as cosmetic raw materials or are very unstable and are difficult to deliver to the skin. Therefore, a special stabilization system and delivery system are required. There is a problem that it is not visible. The retinoid, which is an active ingredient for improving the wrinkles of the skin, is used for inhibiting collagenase and increasing collagen synthesis, thereby improving photoaging phenomenon such as wrinkle formation and reduction in elasticity. However, since it is very sensitive to ultraviolet rays, it easily causes a chemical change, which causes adverse effects such as skin irritation and long-term use (Rabe JH, J. Am. Acad. Dermatol., 55: 1-19, 2006). In order to solve the problems of the above-mentioned active ingredients, there is a demand for studies on active ingredients derived from natural products which have proved to be stable.
퓨코스테롤은 해조류에 많이 함유되어 있는 물질로 한국, 중국, 일본 해안 및 아시아 해안 등지에 서식하는 해조류에서 많이 발견되고 있다. 퓨코스테롤의 지금까지 알려진 효능 및 효과는 항발암 작용과 항암활성(Pharmacogn. Mag. 8(29); 60-4, 2012.), 항당뇨 작용(Arch. Pharm. Res. 27(11); 1120-2, 2004.), 항산화 활성(Bioorg. Med. Chem. 17(5); 1963-73, 2009.), 혈중 지질 성분 개선(Biochem. Biophys. Res. Commun. 369(2); 363-8, 2008.), 콜레스테롤 대사 개선(New Phytol. 183(2); 291-300, 2009.), 항균(J. Pharm. Biomed. Anal. 51(2); 450-5, 2010.) 및 항곰팡이 효능(Nat. Prod. Res. 24(15); 1481-7, 2010.) 등이 알려져 있다. Fucoserol is a substance found in many seaweeds and is found in seaweeds living in Korea, China, Japan coast and Asia coast. Previously known efficacy and efficacy of fucoserol has been shown to have anticarcinogenic and anticancer activities (Pharmacogn. Mag. 8 (29); 60-4, 2012.), antidiabetic action (Arch Pharm. Biochem. Biophys. Res. Commun. 369 (2); 363-9), antioxidant activity (Bioorg. Med. Chem. 17 (5); 1963-73, 2009.) 8, 2008.), improvement of cholesterol metabolism (New Phytol. 183 (2); 291-300, 2009.), antibacterial (J. Pharm. Biomed. Fungal efficacy (Nat. Prod. Res. 24 (15); 1481-7, 2010.).
최근 천연 화장품에 대한 소비자의 관심이 증대되고 동시에 해양 자원 소재를 활용하는 많은 화장품들이 출시되면서 해조류도 화장품의 중요한 피부효능을 가진 소재로 연구되고 있다. 하지만, 해조류의 주요성분 중에 하나인 퓨코스테롤에 의한 피부 효능에 대한 연구는 전무한 실정이다.Recently, consumers are interested in natural cosmetics. At the same time, many cosmetics utilizing marine resource materials have been released, and seaweeds are being studied as materials having important skin effect of cosmetics. However, there is no research on the skin effect by fucoserol, which is one of the major components of seaweeds.
이에, 본 발명자들은 해조류에 풍부하게 들어있는 퓨코스테롤이 콜라겐 분해를 억제하고, 콜라겐 생성을 촉진하여 피부노화의 예방 또는 개선, 및 피부 보습 효과가 있다는 것을 검증하여 본 발명을 완성하였다.Thus, the inventors of the present invention have completed the present invention by verifying that fucoserol contained in seaweeds inhibits collagen degradation, promotes collagen production, thereby preventing or improving skin aging and skin moisturizing effect.
따라서 본 발명의 목적은 하기 [화학식 1]로 표시되는 퓨코스테롤을 유효성분으로 포함하는 피부노화 개선 또는 피부보습용 화장료 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a cosmetic composition for improving skin aging or skin moisturizing comprising fucoserol represented by the following formula (1) as an active ingredient.
[화학식 1] [Chemical Formula 1]
. .
상기의 목적을 달성하기 위하여, 본 발명은 하기 [화학식 1]로 표시되는 퓨코스테롤을 유효성분으로 포함하는 피부노화 개선 또는 피부 보습용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for improving skin aging or skin moisturizing comprising fucose terol represented by the following formula (1) as an active ingredient.
[화학식 1] [Chemical Formula 1]
. .
본 발명의 퓨코스테롤은 뜸부기(Pelvetia siliquosa), 다시마, 미역, 녹미채, 큰실말, 붕어마름, 개다시마, 감태, 대황 및 톳 중 어느 하나가 선택된 추출물을 유효성분으로 포함하는 피부노화 개선 또는 피부 보습용 화장료 조성물을 제공하며, 뜸부기 추출물은 물, 탄소수 1 내지 6개의 유기용매, 아임계 및 초임계 유체로 이루어진 군에서 선택된 하나 이상의 용매로 추출된 것을 특징으로 한다.The fucoserol of the present invention can be used for improving skin aging comprising an extract selected from the group consisting of Pelvetia siliquosa, kelp, seaweed, mackerel, balsam, crucian carp, dog kelp, The present invention provides a cosmetic composition for skin moisturizing, wherein the extract is obtained from at least one solvent selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, subcritical and supercritical fluids.
또한, 본 발명의 일실시예에 있어서, 유기용매는 탄소수 1 내지 6개의 알코올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, 헥산, 시클로헥산 및 석유에테르로 이루어진 군에서 어느 하나가 선택된 것을 특징으로 하고, 상기 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는 것이 바람직하다.In one embodiment of the present invention, the organic solvent is any one selected from the group consisting of alcohols having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane and petroleum ether Wherein the composition is selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays It is desirable to have a formulation to be selected.
본 발명은 또한, 상기 조성물은 화장료 조성물, 건강기능식품 조성물 및 치료용 약학 조성물인 것을 제공한다.The present invention also provides a cosmetic composition, a health functional food composition and a therapeutic pharmaceutical composition.
이상 살펴본 바와 같이, 본 발명은 본 발명의 퓨코스테롤을 유효성분으로 포함하는 피부노화 개선 또는 피부 보습용 화장료 조성물을 제공한다. 본 발명의 조성물은 콜라겐 분해효소를 억제하고, 콜라겐의 생성을 촉진하는 효능이 뛰어나 피부노화 개선 또는 피부보습에 효과적이다.As described above, the present invention provides a cosmetic composition for improving skin aging or skin moisturizing, comprising fucoserol of the present invention as an active ingredient. The composition of the present invention inhibits collagenolytic enzyme and is highly effective in promoting the production of collagen, and is effective for improving skin aging or skin moisturizing.
도 1은 본 발명의 퓨코스테롤이 MMP-1의 발현에 미치는 효과를 나타내는 그래프이다.
도 2는 본 발명의 퓨코스테롤이 I형 프로콜라겐 생성에 미치는 효과를 나타내는 그래프이다.1 is a graph showing the effect of fucoserol of the present invention on the expression of MMP-1.
2 is a graph showing the effect of the fucosterol of the present invention on the production of type I procollagen.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 조성물은 하기 [화학식 1]로 표시되는 퓨코스테롤을 유효성분으로 포함하며 항노화 또는 피부보습 증진의 목적으로 사용될 수 있다.The composition of the present invention contains fucoserol represented by the following formula (1) as an active ingredient and can be used for anti-aging or skin moisturizing.
[화학식 1] [Chemical Formula 1]
본 발명의 조성물에서, 상기 퓨코스테롤은 뜸부기(Pelvetia siliquosa), 다시마, 미역, 녹미채, 큰실말, 붕어마름, 개다시마, 감태, 대황, 톳 등의 해조류 혹은 다른 식물로 부터 추출되어 분리된 것일 수 있다. In the composition of the present invention, the fucoserol is extracted from seaweeds or other plants such as Pelvetia siliquosa, kelp, seaweed, mung bean, broad bean, crucian carp, dog kelp, kelp, rhubarb, Lt; / RTI >
본 발명의 뜸부기 추출물은 퓨코스테롤을 포함한다.The scum extract of the present invention includes fucoserol.
본 발명의 뜸부기 추출물은 공지의 천연물 추출방법에 의하여 추출될 수 있으며, 바람직하게는 물, 탄소수 1 내지 6개의 유기용매 및 아임계 또는 초임계 유체로 이루어진 군에서 선택된 하나 이상의 용매로 추출될 수 있으며, 상기 탄소수 1 내지 6개의 유기용매는 탄소수 1 내지 6개의 알코올(alcohol), 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane), 시클로헥산(cyclohexane) 및 석유에테르(petroleum ether)로 이루어진 군 중에서 선택된 것일 수 있다.The extract of the present invention can be extracted by a known natural material extraction method and is preferably extracted with one or more solvents selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, and subcritical or supercritical fluids. , The organic solvent having 1 to 6 carbon atoms may be selected from the group consisting of alcohols having 1 to 6 carbon atoms, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride methylene chloride, hexane, cyclohexane, and petroleum ether.
바람직하게는 본 발명의 뜸부기 추출물은 건조시킨 뜸부기를 식품가공에 적합한 정제수, 에탄올 및 아임계수 또는 초임계 이산화탄소를 이용하여 추출, 정제하여 얻을 수 있거나, 또는 뜸부기 해조류를 직접 압착하여 얻은 오일로부터 분리 정제하여 얻을 수 있다.Preferably, the extract of the present invention can be obtained by extracting and purifying a dried crab crab using purified water suitable for food processing, ethanol and supercritical carbon dioxide, or extracting and purifying the crab seaweed from the obtained oil directly, .
더욱 바람직하게는 본 발명의 뜸부기 추출물은 에탄올 추출물일 수 있으며, 본 발명의 퓨코스테롤은 에탄올을 용매로 하여 뜸부기로부터 추출할 수 있다.More preferably, the fragrance extract of the present invention may be an ethanol extract, and the fucoserol of the present invention may be extracted from the fragrance extract by using ethanol as a solvent.
바람직하게는 본 발명의 퓨코스테롤은 뜸부기로부터 추출될 수 있다. 뜸부기의 추출물로부터 본 발명의 퓨코스테롤의 분리 및 정제는 실리카겔(silica gel)이나 활성 알루미나(alumina)등의 각종 합성수지를 충진한 컬럼 크로마토그래피 및 고성능 액체 크로마토그래피(HPLC) 등을 단독으로 혹은 병행하여 사용할 수 있으나, 추출 및 분리정제 방법이 반드시 상기 방법에 한정되는 것은 아니다. Preferably, the fucosterol of the present invention can be extracted from the scum. The fucoserol of the present invention can be isolated and purified from the extract of the fungicide by using column chromatography and high performance liquid chromatography (HPLC) packed with various synthetic resins such as silica gel and activated alumina, However, the extraction and separation purification method is not necessarily limited to the above method.
본 발명의 퓨코스테롤은 콜라겐 분해를 억제하며, 콜라겐 합성을 촉진하는 효능이 뛰어나다.The fucoserol of the present invention inhibits collagen degradation and is excellent in promoting collagen synthesis.
본 발명의 일실시예에서는 인간 섬유아세포에서 자외선으로 콜라겐 분해효소-1의 생성을 촉진시킨 후 본 발명의 퓨코스테롤을 투여하여 콜라겐 분해효소-1의 생성을 억제시키는지 여부를 측정하였다. 그 결과 본 발명의 퓨코스테롤은 콜라겐 분해효소-1의 생성을 효과적으로 억제시키는 것을 확인하였다.In one embodiment of the present invention, the production of collagenase-1 by ultraviolet light was promoted in human fibroblasts, and then fucoserol of the present invention was administered to determine whether collagenase-1 production was inhibited. As a result, it was confirmed that the fucosterol of the present invention effectively inhibited the production of collagenase-1.
본 발명의 다른 일실시예에서는 인간 섬유아세포에 본 발명의 퓨코스테롤을 투여하여 배양한 후 콜라겐 생성 수준을 측정하였다. 그 결과 본 발명의 퓨코스테롤을 투여한 경우 자외선 조사에 의하여 억제된 콜라겐 생성을 촉진하는 효과가 매우 뛰어난 것을 확인하였다.In another embodiment of the present invention, the fucoserol of the present invention is cultured in human fibroblasts and the level of collagen production is measured. As a result, it was confirmed that the administration of fucoserol of the present invention was very effective in promoting collagen production inhibited by ultraviolet irradiation.
콜라겐 분해효소의 활성 증가 및 이에 따른 피부의 주요 구성성분인 콜라겐의 붕괴는 피부 주름을 발생시키고, 노화를 촉진시키며, 피부 탄력을 감소시킨다.Increased activity of collagenase and collagen collapse, which is a major component of skin, cause wrinkles, accelerate aging, and reduce skin elasticity.
이러한 콜라겐 분해효소를 억제하고 콜라겐 생성을 촉진을 통하여 본 발명의 조성물은 주름형성을 억제하고, 노화를 억제하며, 피부 탄력을 증진시킨다.By inhibiting such collagenolytic enzymes and promoting collagen production, the composition of the present invention inhibits wrinkle formation, suppresses aging, and promotes skin elasticity.
이와 같이 본 발명의 퓨코스테롤은 주름개선, 항노화, 피부탄력 증진을 위한 화장료 조성물, 식품, 식이보조제(dietary supplements), 의약품 등에 유용하게 적용될 수 있다.As described above, the fucoserol of the present invention can be applied to cosmetic compositions for improving wrinkles, anti-aging, skin elasticity, foods, dietary supplements, medicines and the like.
따라서 본 발명은 본 발명의 퓨코스테롤을 유효성분으로 포함하는 피부노화 개선 또는 피부 보습용 화장료 조성물을 제공한다.Accordingly, the present invention provides a cosmetic composition for improving skin aging or skin moisturizing comprising fucoserol of the present invention as an active ingredient.
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
<< 실시예Example 1> 뜸부기 1> 헥산Hexane 추출물의 제조 Preparation of extract
뜸부기(500 g)를 믹서로 분쇄한 다음, 분쇄한 뜸부기 시료를 4배 용적의 n-헥산에 넣고 48시간 상온에서 냉침하여 추출하였다. 추출된 시료는 와트만(Whatman) 2번 여과지로 여과하고, 여과된 추출액을 진공 회전 농축기로 농축하여 용매성분을 제거한 후 약 15.0 g의 뜸부기 n-헥산 추출물을 얻었다. The crusher (500 g) was pulverized with a mixer, and the pulverized crusher sample was added to 4-fold volume of n-hexane and extracted by cooling at room temperature for 48 hours. The extracted sample was filtered with Whatman No. 2 filter paper, and the filtered extract was concentrated using a vacuum rotary condenser to remove solvent components, and then about 15.0 g of a crude extract of n-hexane was obtained.
<< 실시예Example 2> 2> 퓨코스테롤의Fucoserol 분리 및 구조결정 Separation and structure determination
<2-1> <2-1> 퓨코스테롤의Fucoserol 분리 detach
상기 <실시예 1>에서 얻은 농축된 n-헥산 가용 추출물 15 g을 실리카겔 오픈컬럼(70-230mesh, Merck&Co., Whitehouse Station, NJ, USA)에 적재하고 핵산 및 에틸 아세테이트의 혼합한 용매시스템을 이용하여 분취하였다. 상기 분취 순서에 따라서 농도구배로 시간당 1000㎖씩 분획을 수행하여 1000㎖씩 40 개의 하부 분획물로 나눈 후, 그 중 10 번과 30 번 분획물에서 하기 [화학식 1]의 화합물인 퓨코스테롤을 분리(210 mg)하였고, 그 성상을 분석하였다.15 g of the concentrated n-hexane soluble extract obtained in Example 1 above was loaded on a silica gel open column (70-230 mesh, Merck & Co., Whitehouse Station, NJ, USA) and a solvent system comprising a mixture of nucleic acid and ethyl acetate was used . Fractions of 1000 ml per hour were collected at a concentration gradient according to the above sorting order, and divided into 40 lower fractions of 1000 ml each. Fucoserol, a compound of the following formula (1), was isolated from fractions 10 and 30 210 mg) and analyzed for their properties.
<2-2> <2-2> 퓨코스테롤의Fucoserol 구조결정 Structure determination
상기 <2-1>에서 분리된 단일 활성물질의 구조결정을 위하여 1H-NMR 스펙트럼과 13C-NMR 스펙트럼을 각각 500MHz 와 125MHz (용매: CDCl3)에서 측정하였다. 본 화합물은 EI/MS에서 [M]가 m/z 339에서 관측되어 분자량이 412로 판명되었고, 분자식은 C29H48O였다. 이상의 1H-NMR, 13C-NMR, 및 EI/MS에 대한 결과와 기존에 발표된 연구보고(Wang C. et al., Se Pu, 15: 396-9, 1997)를 비교 분석하여 동정한 결과, 상기 실시예 <2-1>에서 분리된 단일물질은 하기 화학식 1로 표시되는 퓨코스테롤 화합물로 확인되었다.In order to determine the structure of the single active material separated in <2-1>, 1 H-NMR spectrum and 13 C-NMR spectrum were measured at 500 MHz and 125 MHz (solvent: CDCl 3), respectively. The compound was found to have a molecular weight of 412 with [M] observed at m / z 339 in EI / MS, and the molecular formula was C29H48O. (Wang C. et al., Se Pu, 15: 396-9, 1997) were compared with the results of 1 H-NMR, 13 C-NMR and EI / The single substance isolated in Example <2-1> was identified as a fucosterol compound represented by the following formula (1).
[화학식 1][Chemical Formula 1]
<< 실시예Example 3> UV로 유도된 콜라겐 분해효소-1 억제 측정 실험 3> UV-induced collagenase-1 inhibition assay
상기 <실시예 2>를 통해 얻은 퓨코스테롤의 콜라겐 분해효소-1(Matrix Metalloproteinase-1, MMP-1) 억제 효능을 측정하였다.(Matrix Metalloproteinase-1, MMP-1) inhibitory effect of fucoserol obtained through Example 2 was measured.
먼저, 2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 24-공 평판배양기(24-well microtiter plate)에 인간의 섬유 아세포를 1×105 세포/ 공(well)이 되도록 넣고, 90% 정도 자랄 때까지 배양하였다. 그 후 무혈청 DMEM 배지에 녹여진 상기 <실시예 2>를 통해 얻은 퓨코스테롤 0.5 μΜ, 1 μΜ, 5 μΜ 농도로 24시간 동안 처리한 후, UV조사기를 이용하여 15 mJ을 조사하였다. 그 후 무혈청 DMEM 배지에 녹여진 상기 <실시예 2>의 퓨코스테롤 0.5 μΜ, 1 μΜ, 5 μΜ 농도로 추가로 처리하였다. 24시간 경과한 다음 세포배양액을 채취하여 원심분리하고 상등액만 수확하였다.First, human fibroblasts were plated at 1 × 10 5 cells / well in a 24-well microtiter plate containing 2.5% fetal bovine serum-containing DMEM (Dulbecco's Modified Eagle's Media) , And cultured until it grew to about 90%. Thereafter, the cells were treated with fucoserol (0.5 μM, 1 μM, and 5 μM) obtained through the above <Example 2> dissolved in serum-free DMEM medium for 24 hours, and then irradiated with 15 mJ using a UV irradiator. Thereafter, the cells were further treated with 0.5 μM, 1 μM, and 5 μM of fucoserol in the above Example 2 dissolved in serum-free DMEM medium. After 24 hours, the cell culture was collected, centrifuged and only the supernatant was harvested.
이후, 채취한 상등액으로부터 콜라겐 분해효소-1 측정키트(QIA55, Merch & Co., 미국)를 이용하여 콜라겐 분해효소-1 생성정도를 측정하였다. 먼저, 콜라겐 분해효소 1차 항체가 균일하게 도포된 96-공 평판(96-well plate)에 채취된 상기 세포배양액을 넣고 2시간 동안 항원-항체 반응을 상온에서 실시하였다. 2시간 후 발색단이 결합된 1차 콜라겐 항체를 96-공 평판(96-well plate)에 넣고 1시간 동안 반응시켰다. 1시간 후 발색유발물질을 넣어 실온에서 30분간 발색을 유발시킨 후 다시 종결버퍼를 넣어 반응(발색)을 중지시키면 반응액의 색깔은 노란색을 띄며 반응 진행의 정도에 따라 노란색의 정도가 다르게 나타났다. 노란색을 띠는 96-공 평판(96-well plate)의 흡광도를 흡광계를 이용하여 450/540nm에서 측정하였다. Then, the degree of collagenase-1 production was measured using the collagenase-1 measurement kit (QIA55, Merch & Co., USA) from the supernatant. First, the cell culture solution collected in a 96-well plate uniformly coated with collagenase primary antibody was added and antigen-antibody reaction was performed at room temperature for 2 hours. After 2 hours, the primary collagen antibody bound to the chromophore was placed in a 96-well plate and reacted for 1 hour. After 1 hour, the color development inducing substance was added, and coloration was induced at room temperature for 30 minutes. When the reaction (color development) was stopped by adding a finalization buffer, the color of the reaction solution became yellow and the degree of yellow was different depending on the progress of the reaction. The absorbance of a yellow 96-well plate was measured at 450/540 nm using a spectrophotometer.
그 결과, 퓨코스테롤이 콜라겐 분해효소-1 억제효능에 뛰어난 효과를 가짐을 알 수 있었다(도 1참고).As a result, it was found that fucosterol had an excellent effect on inhibition of collagenase-1 (see Fig. 1).
<< 실시예Example 4> 콜라겐 생성 증진 효능 실험 4> Collagen production promotion effect experiment
상기 <실시예 2>를 통해 얻은 퓨코스테롤에 대하여 콜라겐 생성 증진 효능을 측정하였다.The effect of enhancing collagen production in fucoserol obtained through Example 2 was measured.
먼저, 2.5%의 우태아 혈청이 함유된 DMEM(Dulbecco's Modified Eagle's Media) 배지가 들어있는 24-공 평판배양기(24-well microtiter plate)에 인간의 섬유 아세포를 1×105 세포/ 공(well)이 되도록 넣고, 90% 정도 자랄 때까지 배양하였다. 그 후 무혈청 DMEM 배지에 녹여진 상기 <실시예 2>를 통해 얻은 퓨코스테롤 0.5 μΜ, 1 μΜ, 5 μΜ 농도로 24시간 동안 처리한 후, UV조사기를 이용하여 15 mJ을 조사하였다. 그 후 무혈청 DMEM 배지에 녹여진 상기 <실시예 2>를 통해 얻은 퓨코스테롤 0.5 μΜ, 1 μΜ, 5 μΜ 농도로 추가로 처리하였다. 24시간 경과한 다음 세포배양액을 채취하여 원심분리하고 상등액만 수확하여, 콜라겐 합성의 지표가 되는 펩타이드(procollagen type-Ⅰ C-peptide, PIP)를 ELISA 키트(MK101, Takara Bio Ink., 일본)를 이용하여 콜라겐 생성에 미치는 영향을 정량적으로 측정하였다. First, human fibroblasts were plated at 1 × 10 5 cells / well in a 24-well microtiter plate containing 2.5% fetal bovine serum-containing DMEM (Dulbecco's Modified Eagle's Media) , And cultured until it grew to about 90%. Thereafter, the cells were treated with fucoserol (0.5 μM, 1 μM, and 5 μM) obtained through the above <Example 2> dissolved in serum-free DMEM medium for 24 hours, and then irradiated with 15 mJ using a UV irradiator. The cells were further treated with 0.5 μM, 1 μM and 5 μM of fucoserol obtained in Example 2, which was dissolved in serum-free DMEM medium. After 24 hours, the cell culture medium was collected and centrifuged. Only the supernatant was harvested and the peptide (procollagen type-Ⅰ C-peptide, PIP) as an index of collagen synthesis was subjected to ELISA kit (MK101, Takara Bio Ink., Japan) And the effect on collagen production was quantitatively measured.
먼저, 프로콜라겐에 대한 마우스 단클론 항체가 균일하게 도포된 96-공 평판(96-well plate)에 퍼록시다제(peroxidase)로 표지한 항체-PIP 컨쥬게이트를 넣어 반응시킨다. 그 후 채취한 상기 세포배양액을 넣고 37℃ 인큐베이터에서 3시간 동안 반응시키고 기질용액을 넣어 발색시킨다. 실온에서 15분 방치 후 반응중지용액을 넣어 반응을 중지시키고 흡광계를 이용하여 450 nm에서 흡광도를 측정하였다.First, a peroxidase-labeled antibody-PIP conjugate is added to a 96-well plate to which a mouse monoclonal antibody against procollagen is uniformly applied. Subsequently, the cell culture solution thus obtained is added, reacted for 3 hours in an incubator at 37 ° C, and a substrate solution is added to develop color. After standing at room temperature for 15 minutes, the reaction was stopped by putting the reaction stop solution and absorbance was measured at 450 nm using a light absorptometer.
그 결과, 퓨코스테롤이 콜라겐 생성에 대한 효과가 매우 우수함을 알 수 있다(도 2참고).As a result, it can be seen that the effect of fucosterol on collagen production is excellent (see FIG. 2).
<< 제형예Formulation Example 1 - 화장품> 1 - Cosmetics>
<1-1> 영양화장수(<1-1> Nourishing Lotion ( 밀크로션Milk lotion ))
상기 <실시예 2>의 퓨코스테롤을 하기 [표 1]의 영양화장수 제형 비율대로 하여 통상적인 방법에 따라 영양화장수를 제조하였다.The nutritional lotion was prepared according to the conventional method according to the formulation ratio of fucoserol of Example 2 as shown in Table 1 below.
<1-2> 유연화장수(스킨로션)<1-2> Flexible longevity (skin lotion)
상기 <실시예 2>의 퓨코스테롤을 하기 [표 2]의 유연화장수 제형 비율대로 하여 통상적인 방법에 따라 유연화장수를 제조하였다.The fucoserol of Example 2 was prepared according to a conventional method according to the formulation ratio of the softening water of Table 2 below.
<1-3> 영양크림<1-3> Nourishing cream
상기 <실시예 2>의 퓨코스테롤을 하기 [표 3]의 영양크림 제형 비율대로 하여 통상적인 방법에 따라 영양크림을 제조하였다.Nutritive creams were prepared according to a conventional method according to the nutritional cream formulation ratios shown in the following Table 2 for fucoserol of Example 2.
<1-4> 마사지크림<1-4> Massage Cream
상기 <실시예 2>의 퓨코스테롤을 하기 [표 4]의 마사지크림 제형 비율대로 하여 통상적인 방법에 따라 마사지크림을 제조하였다.A massage cream was prepared according to a conventional method by using the fucoserol of Example 2 as the ratio of the massage cream of the following [Table 4].
<1-5> 팩<1-5> Pack
상기 <실시예 2>의 퓨코스테롤을 하기 [표 5]의 팩 제형 비율대로 하여 통상적인 방법에 따라 팩을 제조하였다.A pack was prepared according to a conventional method according to the pack formulation ratio of the following [Table 5].
<1-6> 젤<1-6> Gel
상기 <실시예 2>의 퓨코스테롤을 하기 [표 6]의 젤 제형 비율대로 하여 통상적인 방법에 따라 젤을 제조하였다.The fucoserol of Example 2 was prepared according to a conventional method according to the ratio of the gel formulation shown in Table 6 below.
<< 제형예Formulation Example 2 - 건강기능식품> 2 - Health functional foods>
<2-1> 건강기능식품의 제조<2-1> Production of Health Functional Food
상기 <실시예 2>의 퓨코스테롤 1000mg, 비타민 A 아세테이트 70ug, 비타민 E 1.0mg, 비타민 B1 0.13mg, 비타민 B2 0.15mg, 비타민 B6 0.5mg, 비타민 B12 0.2ug, 비타민 C 10mg, 비오틴 10ug, 니코틴산아미드 1.7mg, 엽산 50ug, 판토텐산 칼슘 0.5mg, 황산제1철 1.75mg, 산화아연 0.82mg, 탄산마그네슘 25.3mg, 제1인산칼륨 15mg, 제2인산칼슘 55mg, 구연산칼륨 90mg, 탄산칼슘 100mg, 염화마그네슘 24.8mg를 혼합하여 제조할 수 있으며, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Vitamin E acetate, 70 mg of vitamin A acetate, 0.1 mg of vitamin B1, 0.15 mg of vitamin B2, 0.5 mg of vitamin B6, 0.2 g of vitamin B12, 10 mg of vitamin C, 10 g of biotin, 10 g of nicotinic acid Amide 1.7 mg,
<2-2> 건강음료의 제조<2-2> Manufacture of health drinks
상기 <실시예 2>의 퓨코스테롤 1000mg, 구연산 1000mg, 올리고당 100g, 매실농축액 2g, 타우린 1g에 정제수를 가하여 전체 900ml 통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2L용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 건강음료 조성물 제조에 사용할 수 있다.Purified water was added to 1,000 mg of fucoserol in Example 2, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of a plum concentrate and 1 g of taurine to mix the above components according to a general health drink manufacturing method in a total of 900 ml, After stirring and heating at 85 ° C, the resulting solution is filtered and sterilized in a sterilized 2 L vessel, sterilized and stored in the refrigerator for use in the manufacture of a health beverage composition.
<2-3> <2-3> 츄잉껌Chewing gum
껌 베이스 20 중량%, 설탕 76.9 중량%, 향료 1 중량% 및 물 2 중량%와 상기 <실시예 2>의 퓨코스테롤 0.1 중량%를 배합하여 통상의 방법으로 츄잉껌을 제조하였다.Chewing gum was prepared by combining 20% by weight of a gum base, 76.9% by weight of sugar, 1% by weight of a flavor and 2% by weight of water and 0.1% by weight of fucoserol in Example 2.
<2-4> 캔디<2-4> Candy
설탕 60 중량%, 물엿 39.8 중량% 및 향료 0.1 중량%와 상기 <실시예 2>의 퓨코스테롤 0.1 중량%를 배합하여 통상의 방법으로 캔디를 제조하였다.Candy was prepared by mixing 60% by weight of sugar, 39.8% by weight of starch syrup, 0.1% by weight of flavor and 0.1% by weight of fucoserol of Example 2 described above.
<2-5> <2-5> 비스켓Biscuit
박력 1급 25.59 중량%, 중력 1급 22.22 중량%, 정백당 4.80 중량%, 식염 0.73 중량%, 포도당 0.78 중량%, 팜쇼트닝 11.78 중량%, 암모늄 1.54 중량%, 중조 0.17 중량%, 중아황산나트륨 0.16 중량%, 쌀가루 1.45 중량%, 비타민 B₁0.0001 중량%, 비타민 B₂0.0001 중량%, 밀크향 0.04 중량%, 물 20.6998 중량%, 전지분유 1.16 중량%, 대용분유 0.29 중량%, 제1인산칼슘 0.03 중량%, 살포염 0.29 중량% 및 분무유 7.27 중량%와 상기 <실시예 2>의 퓨코스테롤 중량%를 배합하여 통상의 방법으로 비스켓을 제조하였다.A mixture of 0.75% by weight of sodium chloride, 0.78% by weight of glucose, 11.78% by weight of palm shortening, 1.54% by weight of ammonium, 0.17% by weight of sodium bicarbonate and 0.16% by weight of sodium bisulfite, 25.59% by weight of Grade I, 22.22% 1.45 wt% of rice flour, 0.0001 wt% of vitamin B1, 0.0001 wt% of vitamin B2, 0.04 wt% of milk fractions, 20.6998 wt% of water, 1.16 wt% of whole milk powder, 0.29 wt% 0.29% by weight of spray salt and 7.27% by weight of spray oil and the weight percentage of fucosterol in Example 2 were blended to prepare a biscuit by a conventional method.
<< 제형예Formulation Example 3 - 의약품> 3 - Medicines>
<3-1> <3-1> 산제Powder
상기 <실시예 2>의 퓨코스테롤 50mg, 결정셀룰로오즈 2g을 혼합한 후 통상의 산제 제조방법에 따라서 기밀포에 충진하여 산제를 제조하였다.50 mg of fucoserol of Example 2 and 2 g of crystalline cellulose were mixed and filled in an airtight cell according to a conventional acid production method to prepare a powder.
<3-2> 정제<3-2> Purification
상기 <실시예 2>의 퓨코스테롤 50mg, 결정셀룰로오즈 400mg, 스테아린산 마그네슘 5mg을 혼합한 후 통상의 정제 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing 50 mg of fucosterol, 400 mg of crystalline cellulose and 5 mg of magnesium stearate in Example 2, tablets were prepared by tableting according to a conventional tablet preparation method.
<3-3> <3-3> 캡슐제Capsule
상기 <실시예 2>의 퓨코스테롤 30mg, 유청단백질 100mg, 결정셀룰로오즈 400mg, 스테아린산 마그네슘 6mg을 혼합한 후 통상의 캡슐제 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.30 mg of fucose terol of Example 2, 100 mg of whey protein, 400 mg of crystalline cellulose and 6 mg of magnesium stearate were mixed and filled in gelatin capsules according to a conventional preparation method to prepare capsules.
<3-4> 주사제<3-4>
통상의 주사제 제조방법에 따라 활성성분을 주사용 증류수에 용해하고 pH를 약 7.5로 조절한 다음 상기 <실시예 2>의 퓨코스테롤 100mg, 주사용 증류수, pH 조절제를 혼합하여 2ml 용량의 앰플에 충진하고 멸균시켜서 주사제를 제조하였다.The active ingredient was dissolved in distilled water for injection and the pH was adjusted to about 7.5. Then, 100 mg of fucoserol in Example 2, distilled water for injection, and pH adjuster were mixed and added to a 2 ml volume ampoule Filled and sterilized to prepare an injection.
따라서, 본 발명은 본 발명의 퓨코스테롤을 유효성분으로 포함하는 피부주름 또는 피부노화 개선용 화장료 조성물을 제공한다. 본 발명의 조성물은 콜라겐 분해효소를 억제하고, 콜라겐의 생성을 촉진하는 효능이 뛰어나 피부노화 개선 또는 피부보습에 효과적이어서 산업상 이용가능성이 높다.Accordingly, the present invention provides a cosmetic composition for improving skin wrinkles or skin aging comprising fucoserol of the present invention as an active ingredient. The composition of the present invention is highly effective in suppressing collagenase and promoting the production of collagen, and thus being effective in improving skin aging or skin moisturizing, and thus being highly industrially applicable.
Claims (10)
[화학식 1]
.
A cosmetic composition for skin moisturizing comprising fucoserol represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
.
상기 퓨코스테롤은 뜸부기(Pelvetia siliquosa), 다시마, 미역, 녹미채, 큰실말, 붕어마름, 개다시마, 감태, 대황 및 톳으로 이루어진 군에서 선택된 어느 하나로부터 추출된 것을 특징으로 하는 피부 보습용 화장료 조성물.
The method according to claim 1,
Wherein the fucoserol is extracted from any one selected from the group consisting of Pelvetia siliquosa, kelp, seaweed, seaweed, seaweed, crucian carp, dog kelp, Composition.
상기 퓨코스테롤은 물, 탄소수 1 내지 6개의 유기용매, 아임계 및 초임계 유체로 이루어진 군에서 선택된 하나 이상의 용매로 추출된 것을 특징으로 하는 피부보습용 화장료 조성물.
The method according to claim 1,
Wherein the fucoserol is extracted with at least one solvent selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, subcritical and supercritical fluids.
상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는 것을 특징으로 하는 피부 보습용 화장료 조성물.
The method according to claim 1,
The cosmetic composition may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray And a cosmetic composition for skin moisturizing.
[화학식 1]
.
A health functional food for skin moisturizing comprising fucoserol represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
.
상기 퓨코스테롤은 뜸부기(Pelvetia siliquosa), 다시마, 미역, 녹미채, 큰실말, 붕어마름, 개다시마, 감태, 대황 및 톳으로 이루어진 군에서 선택된 어느 하나로부터 추출된 것을 특징으로 하는 피부 보습용 건강기능식품.
6. The method of claim 5,
Wherein the fucoserol is extracted from any one selected from the group consisting of Pelvetia siliquosa, kelp, sea bream, sea bream, broad bean sprout, crucian carp, dog kelp, Functional foods.
상기 퓨코스테롤은 물, 탄소수 1 내지 6개의 유기용매, 아임계 및 초임계 유체로 이루어진 군에서 선택된 하나 이상의 용매로 추출된 것을 특징으로 하는 피부 보습용 건강기능식품.
6. The method of claim 5,
Wherein said fucoserol is extracted with at least one solvent selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, subcritical and supercritical fluids.
[화학식 1]
.
A skin moisturizing pharmaceutical composition comprising fucoserol represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
.
상기 퓨코스테롤은 뜸부기(Pelvetia siliquosa), 다시마, 미역, 녹미채, 큰실말, 붕어마름, 개다시마, 감태, 대황 및 톳으로 이루어진 군에서 선택된 어느 하나로부터 추출된 것을 특징으로 하는 피부 보습용 약학적 조성물.
9. The method of claim 8,
Wherein the fucoserol is extracted from any one selected from the group consisting of Pelvetia siliquosa, kelp, seaweed, seaweed, giant seaweed, crucian carp, dog kelp, Gt;
상기 퓨코스테롤은 물, 탄소수 1 내지 6개의 유기용매, 아임계 및 초임계 유체로 이루어진 군에서 선택된 하나 이상의 용매로 추출된 것을 특징으로 하는 피부 보습용 약학적 조성물.
9. The method of claim 8,
Wherein the fucoserol is extracted with at least one solvent selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, subcritical and supercritical fluids.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170056923A KR101914441B1 (en) | 2017-05-04 | 2017-05-04 | Cosmetic compositions for improving skin moisturizing comprising fucosterol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170056923A KR101914441B1 (en) | 2017-05-04 | 2017-05-04 | Cosmetic compositions for improving skin moisturizing comprising fucosterol |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120059576A Division KR101904501B1 (en) | 2012-06-04 | 2012-06-04 | Cosmetic compositions for improving skin wrinkles or skin elasticity comprising fucosterol |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170052556A KR20170052556A (en) | 2017-05-12 |
KR101914441B1 true KR101914441B1 (en) | 2018-11-02 |
Family
ID=58740598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170056923A KR101914441B1 (en) | 2017-05-04 | 2017-05-04 | Cosmetic compositions for improving skin moisturizing comprising fucosterol |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101914441B1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108553938A (en) * | 2018-05-22 | 2018-09-21 | 江苏农牧科技职业学院 | A kind of method of Subcritical Water Extraction peony seeds sterol |
KR102189415B1 (en) * | 2019-02-11 | 2020-12-11 | 코스맥스바이오 주식회사 | Compositions for preventing or improving the UV-induced skin damage comprising the extract of Eisenia bicyclis as an active ingredient |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029818A2 (en) * | 2004-09-16 | 2006-03-23 | Dsm Ip Assets B.V. | Cosmetic compositions containing an hydroxamic acid compound optionally in combination with a retinoid |
-
2017
- 2017-05-04 KR KR1020170056923A patent/KR101914441B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029818A2 (en) * | 2004-09-16 | 2006-03-23 | Dsm Ip Assets B.V. | Cosmetic compositions containing an hydroxamic acid compound optionally in combination with a retinoid |
Also Published As
Publication number | Publication date |
---|---|
KR20170052556A (en) | 2017-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101841255B1 (en) | Composition for improving skin wrinkle and enhancing elasticity | |
KR101434653B1 (en) | Novel use of flavon compounds | |
KR101973639B1 (en) | Composition for anti oxidation containing extract of soybean leaf | |
KR102022622B1 (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
EP2200574B1 (en) | Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same | |
JP2003146837A (en) | Skin cosmetic and food/drink for cosmetrogical use | |
KR101758144B1 (en) | Composition for anti-aging containing youngia denticulata extract | |
KR101914441B1 (en) | Cosmetic compositions for improving skin moisturizing comprising fucosterol | |
KR101904501B1 (en) | Cosmetic compositions for improving skin wrinkles or skin elasticity comprising fucosterol | |
US20170196797A1 (en) | Composition containing glycine gracilis oil | |
KR20150113717A (en) | Compositions for Improving Skin Aging Comprising of Allium hookeri Extract | |
KR102014961B1 (en) | Composition for anti oxidation containing extract of soybean pod | |
KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
JP2011032177A (en) | Inhibitor of kit cleavage | |
KR20140057040A (en) | Compositions for improving skin aging comprising piperine compounds as active ingredients | |
KR102014960B1 (en) | Composition for anti oxidation containing extract of soybean root | |
KR20150019582A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
KR101989067B1 (en) | Composition Containing Coumestrin | |
KR102326086B1 (en) | Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient | |
KR101988988B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening | |
KR101940055B1 (en) | Composition for skin moisturizing containing extract of soybean leaf | |
KR101870210B1 (en) | Anti-aging composition comprising aster plant extracts | |
KR20180072381A (en) | Composition for improving skin condition comprising extract of Pisum sativum var. arvense (L.) Poir. | |
JP2003183173A (en) | Skin care preparation and beautifying food or beverage product | |
KR20240080276A (en) | Composition for Anti-Oxidant, Anti-Inflammatory and Anti-Obesity Comprising Purple Tea Extract as Active Ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |